Detalles de la búsqueda
1.
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
Lancet Oncol
; 22(6): 813-823, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000245
2.
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Acta Neuropathol
; 141(6): 945-957, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740099
3.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Lancet
; 390(10103): 1645-1653, 2017 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28801186
Resultados
1 -
3
de 3
1
Próxima >
>>